Clinical results of a multicenter study with sulbactam/ampicillin for the treatment of patients with lower respiratory and urinary tract infections.

Abstract

A total of 124 patients with lower respiratory tract (44) or urinary tract infections (80) were enrolled in an open, multicenter study to evaluate the efficacy and tolerability of sulbactam/ampicillin, administered at the dosage of 3 g/die by intramuscular route. Pretreatment pathogens from patients with lower respiratory tract infections included: Streptococcus alpha-haemolyticus in 8 cases, Streptococcus beta-haemolyticus in 2 cases, Staphylococcus albus in 7 cases, Haemophilus influenzae in 7 cases, Staphylococcus aureus in 6 cases, Klebsiella oxytoca in 5 cases, Staphylococcus epidermidis in 3 cases, Streptococcus pneumoniae in 3 cases, Escherichia coli in 2 cases; in one subject (2.75%), no microorganisms were isolated. In vitro, 36 isolates (84%) were sensitive to SA and 7 (16%) were resistant. At the end of therapy, all the causative pathogens sensitive to sulbactam/ampicillin were eliminated. In patients with urinary tract infections, pretreatment pathogens were: E. coli in 40 cases, S. albus in 16 cases, Proteus mirabilis in 8 cases, Enterobacter agglomerans in 6 cases, Proteus vulgaris in 3 cases, Streptococcus faecalis in 3 cases, Streptococcus liquefaciens in 2 cases, Pseudomonas aeruginosa in 2 cases. In vitro, 64 isolates (80%) were sensitive to sulbactam/ampicillin and 16 (20%) were resistant. At the end of therapy, 63 out of the 64 pathogens sensitive to sulbactam/ampicillin were eliminated; in one case the therapy was interrupted due to adverse effect. Clinical efficacy: in subjects with lower respiratory tract infections, sulbactam/ampicillin cured 32 patients (72.72%) and ameliorated the clinical status of 8 patients (18.18%); efficacy rate: 90.9%).(ABSTRACT TRUNCATED AT 250 WORDS)

• Authors: C De Simone, F Chiodo, S Delia, G Pastore, G Scalise, F Sorice, G Tonietti, C Zanussi, M Paoloni, M Gargiulo
• Journal: Journal of chemotherapy (Florence, Italy) (J Chemother) Vol. 3 Issue 5 Pg. 321-7 (Oct 1991) ISSN: 1120-009X [Print] England
• PMID: 1809811 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Culture Media
• sultamicillin
• Ampicillin
• beta-Lactamases
• Sulbactam

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Ampicillin (administration & dosage, adverse effects, therapeutic use)
• Culture Media
• Drug Synergism
• Drug Therapy, Combination (administration & dosage, adverse effects, therapeutic use)
• Female
• Gram-Negative Bacterial Infections (drug therapy)
• Humans
• Male
• Middle Aged
• Respiratory Tract Infections (drug therapy, microbiology)
• Staphylococcal Infections (drug therapy)
• Streptococcal Infections (drug therapy)
• Sulbactam (administration & dosage, adverse effects, therapeutic use)
• Urinary Tract Infections (drug therapy, microbiology)
• beta-Lactamases (metabolism)